125 results
8-K
EX-99.1
MNPR
Monopar Therapeutics Inc
8 Aug 23
Monopar Provides Encouraging Camsirubicin Clinical Data Update
7:00am
Design and GEIS Collaboration
The purpose of this dose escalation Phase 1b trial is to determine the maximum tolerated dose (MTD) of camsirubicin
8-K
EX-99.1
MNPR
Monopar Therapeutics Inc
1 Jun 23
Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update
7:01am
Collaboration
The purpose of this 3+3 dose escalation Phase 1b trial is to determine the maximum tolerated dose (MTD) of camsirubicin. Once the MTD
8-K
EX-1.1
6sica1len2gcqk14cm
20 Apr 22
Entry into a Material Definitive Agreement
5:23pm
424B5
jvp9el3benetgq
20 Apr 22
Prospectus supplement for primary offering
5:00pm